肺炎管理临床试验评估异质性结局和测量工具
该系统评价基于前瞻性方案检索MEDLINE/PubMed、Cochrane CENTRAL和临床试验注册库,纳入280项评估成人肺炎管理的随机对照试验,识别出43个不同结局和108种测量工具,发现结局和测量工具报告存在显著异质性,患者和医务人员重要的结局常被省略,支持制定严格的核心结局集。
要点
- 280项随机对照试验中,115项(41.1%)纳入危重患者,165项(58.9%)以非危重患者为主。
- 几乎全部试验报告临床/生理结局(97.5%),安全性(63.2%)、死亡率(56.4%)、资源利用(48.6%)和生命影响(11.8%)较少涉及。
- 最常报告的结局为治疗成功(60.7%)、死亡率(56.4%)和不良事件(41.1%)。
核心结论
- 本综述揭示肺炎管理临床试验报告的结局和测量工具存在显著异质性,患者和医务人员重要的结局常被省略,支持需要严格的核心结局集,如欧洲呼吸学会正在制定的核心结局集。
研究设计与样本
- 基于前瞻性方案的系统评价,检索MEDLINE/PubMed、Cochrane CENTRAL和临床试验注册库中评估成人肺炎管理的进行中或已完成临床试验。
- 共纳入280项符合条件的随机对照试验,其中115项(41.1%)纳入危重患者,165项(58.9%)以非危重患者为主。
主要发现
- 识别出43个不同结局和108种测量工具,排除未验证的量表和问卷。
- 几乎全部试验报告临床/生理结局(97.5%),安全性(63.2%)、死亡率(56.4%)、资源利用(48.6%)和生命影响(11.8%)较少报告。
- 最常报告的结局为治疗成功(60.7%)、死亡率(56.4%)和不良事件(41.1%)。
- 测量工具选择存在显著变异,约三分之二的工具在280项随机对照试验中使用不足10项。
- 无患者报告结局在10项或以上随机对照试验中使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To inform clinical practice guidelines, randomized controlled trials (RCTs) of the management of pneumonia need to address the outcomes that are most important to patients and health professionals using consistent instruments, to enable results to be compared, contrasted, and combined as appropriate. This systematic review describes the outcomes reported in clinical trials of pneumonia management and the instruments used to measure these outcomes. STUDY DESIGN AND SETTING: Based on a prospective protocol, we searched MEDLINE/PubMed, Cochrane CENTRAL and clinical trial registries for ongoing or completed clinical trials evaluating pneumonia management in adults in any clinical setting. We grouped reported outcomes thematically and classified them following the COMET Initiative's taxonomy. We describe instruments used for assessing each outcome. RESULTS: We found 280 eligible RCTs of which 115 (41.1%) enrolled critically ill patients and 165 (58.9%) predominantly noncritically ill patients. We identified 43 distinct outcomes and 108 measurement instruments, excluding nonvalidated scores and questionnaires. Almost all trials reported clinical/physiological outcomes (97.5%). Safety (63.2%), mortality (56.4%), resource use (48.6%) and life impact (11.8%) outcomes were less frequently addressed. The most frequently reported outcomes were treatment success (60.7%), mortality (56.4%) and adverse events (41.1%). There was significant variation in the selection of measurement instruments, with approximately two-thirds used in less than 10 of the 280 RCTs. None of the patient-reported outcomes were used in 10 or more RCTs. CONCLUSION: This review reveals significant variation in outcomes and measurement instruments reported in clinical trials of pneumonia management. Outcomes that are important to patients and health professionals are often omitted. Our findings support the need for a rigorous core outcome set, such as that being developed by the European Respiratory Society.
引用
- Mathioudakis AG, Fally M, Hansel J, et al. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments. J Clin Epidemiol. 2023. PMID: 37898460. doi:10.1016/j.jclinepi.2023.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。